FierceBiotech Radio
Medical
FierceBiotech brings you interviews and analysis from around the biotech, pharma and medical device industries.
Location:
United States
Description:
FierceBiotech brings you interviews and analysis from around the biotech, pharma and medical device industries.
Language:
English
Episodes
Pricing drugs, selling hype and how we got here in the first place
5/15/2018
FierceBiotech chats with a pair of lawyers about how drug pricing is unique in the U.S. and how the biopharma environment lends itself to selling hype and securities fraud.
Duration:00:15:46
The FierceMadness drug name showdown and how do drugs get their zany names anyway?
3/13/2018
Fierce editors discuss the 2018 FierceMadness drug name tournament, its origins, and our favorites heading into the competition, while Scott Piergrossi, vice president of creative development at the Brand Institute, talks us through the history of drug naming, his team's creative process, and drug-naming styles and strategies.
Duration:00:21:26
Back from the dead: FierceBiotech Radio at the Battle of the Biotech Bands
10/31/2017
FierceBiotech Radio rose from the grave for this special Halloween episode where we sat down with some of the scientists, account associates and operations managers who competed in 2017's Battle of the Biotech Bands.
Duration:00:09:45
GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster
3/18/2016
Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial and Valeant Pharmaceuticals' rough week.
Duration:00:28:41
The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'
2/26/2016
Fierce editors discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts to undercut Novo Nordisk in diabetes, and a novel approach to regulating drug costs.
Duration:00:41:25
Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals
2/18/2016
Fierce editors discuss the rise of TV ads for specialty drugs, signs of life in the biotech IPO scene, and the case for Intercept Pharmaceuticals as a buyout target.
Duration:00:39:22
Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars
2/11/2016
Fierce editors discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.
Duration:00:40:29
Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover
2/4/2016
Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to right the ship.
Duration:00:36:40
Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup
1/8/2016
Fierce editors discuss Shire's increasingly complicated ambition to acquire Baxalta, the changing climate of biotech venture capital and the future of Valeant Pharmaceuticals.
Duration:00:22:36
The burning hole in Gilead's $25B pocket and AbbVie's future in hematology
12/10/2015
Fierce editors discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back at AbbVie's blockbuster buyout of Pharmacyclics and a thoughtful consideration of how a certain biotech entrepreneur is bringing attention to an FDA loophole.
Duration:00:19:51
Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place
12/3/2015
In an episode free of Valeant Pharmaceuticals and Martin Shkreli, Fierce editors discuss a Senate investigation into Gilead Sciences' pricing of the hepatitis C drug Sovaldi, BioMarin's efforts to win approval for a rare disease treatment and GlaxoSmithKline's latest woes in China.
Duration:00:24:30
The ins and outs of 'Pfizergan,' whatever it is Martin Shkreli's doing and the end of two takeover battles
11/24/2015
Fierce editors discuss the long-awaited merger agreement between Pfizer and Allergan, Martin Shkreli's CEO double duty, and the whimpering conclusion of two hostile takeovers.
Duration:00:28:34
Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit
11/12/2015
Fierce editors discuss Sanofi's uninspiring forecast, Amgen's return to high-dollar dealmaking and a lawsuit that accuses a drug company of deliberately being bad at making drugs.
Duration:00:32:02
Fraud's not that big of a deal: the Valeant story, according to Bill Ackman
11/5/2015
Fierce editors discuss the latest turns in the Valeant Pharmaceuticals saga, the seeming inevitability of a Pfizer-Allergan merger, and Shire's up-and-down efforts to buy stuff it wants.
Duration:00:29:45
Valeant's semantic innovation, Pfizer's future and the slow trickle of biotech IPOs
10/29/2015
Fierce editors discuss a fascinating Valeant Pharmaceuticals conference call, Pfizer's desire for a big buyout and the creaky world of biotech IPOs.
Duration:00:25:07
Doomsdays for Valeant, Biogen and biotech VC
10/22/2015
Fierce editors discuss a rough day for Valeant Pharmaceuticals and Biogen, plus the changing in winds in biotech venture capital.
Duration:00:21:49
Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand
10/15/2015
Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to distance itself from that other Merck.
Duration:00:28:53
Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot
10/8/2015
Fierce editors discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the face of congressional inquiry, and a curious new trend in pharma advertising.
Duration:00:26:29
Valeant feels the Bern, biotech buckles on Wall Street, and Bristol-Myers turns to Family Feud
10/1/2015
Fierce editors discuss how concerns about drug pricing have affected biopharma companies large and small, the latest threat to the biotech bubble, and Bristol-Myers Squibb's interesting televisual choices.
Duration:00:21:42
John Carroll on Turing Pharma and Martin Shkreli
9/22/2015
FierceBiotech's John Carroll discusses his personal experience with the ongoing fallout over Turing Pharmaceuticals' drug pricing and CEO Martin Shkreli's public response.
Duration:00:14:57